Informed Skin›Kybella

Biostimulators

Kybella

Deoxycholic acid (ATX-101)

FDA-approved injectable fat dissolution for submental fullness

Volume LossSagging Jowls
Safe for skin types
Safe forAll Fitzpatrick types I–VI
Use cautionNone specific to skin tone
Avoid ifNone related to Fitzpatrick type

Deoxycholic acid targets adipocyte cell membranes, not melanin. Fat cell destruction and the subsequent inflammatory response are not affected by skin tone or Fitzpatrick type. Efficacy and risk profile are equivalent across all skin tones.

In plain English

A synthetic version of a bile acid is injected into the fat under your chin to permanently destroy those fat cells. FDA-approved, permanent fat reduction -- but each session causes significant swelling and bruising for 1-2 weeks, and nerve injury affecting the smile was documented in 4.3% of Phase 3 trial patients (though all resolved). Requires 2-6 sessions. It works, but the recovery is real and significant.

The science

Deoxycholic acid (ATX-101, brand name Kybella) is a synthetic version of a naturally occurring bile acid that disrupts cell membrane integrity. Injected into submental fat, it causes adipocyte lysis and a subsequent inflammatory response that permanently destroys fat cells. FDA-approved in 2015 specifically for moderate-to-severe submental fullness. The fat reduction is permanent as deoxycholic acid destroys the fat cells; however, marginal mandibular nerve injury (4.3% in Phase 3 trials, all resolved) and significant swelling and bruising (near-universal after each session) make recovery significant.

Why these scores
Medical PromiseHigher is better
7/10

68.2% responder rate vs 20.5% placebo in Phase 3 RCT (n=506); the fat reduction is permanent.

Short-term SafetyHigher is safer
4/10

Swelling and bruising are near-universal and severe enough to affect daily life for 1-2 weeks per session; marginal mandibular nerve injury in 4.3% of Phase 3 patients (all resolved); high injection-site pain.

Long-term SafetyHigher is safer
7/10

Permanent fat reduction with no documented long-term sequelae; permanent nerve injury, though rare, is theoretically possible with poor technique.

Should You Try ThisHigher is better
5/10

Effective but the recovery burden and nerve injury risk, combined with high cost for multiple sessions, make this harder to recommend than the FDA approval alone suggests.

Common misconceptions
✕Myth

“Kybella results in gradual subtle reduction.”

✓Reality

Post-injection swelling is severe and the clinical process involves a significant visible inflammatory response. Patients should plan around 1-2 weeks of visible recovery per session.

✕Myth

“Any fat-dissolving injection is as safe as Kybella.”

✓Reality

Only Kybella and Belkyra have FDA-approved safety and efficacy data at a defined concentration and injection protocol. Compounded or unlicensed deoxycholic acid alternatives have documented cases of skin necrosis and are not equivalent.

What the evidence firmly supports
  • ✓

    68.2% responder rate vs 20.5% placebo in Phase 3 RCT (Rzany et al. 2014, n=506); permanent adipocyte destruction confirmed histologically.

  • ✓

    Marginal mandibular nerve injury documented in 4.3% of Phase 3 trial patients; all cases resolved spontaneously.

Still being studied
  • ?

    Long-term durability of fat reduction beyond 5 years.

  • ?

    Optimal injection technique to minimise marginal mandibular nerve risk.

  • ?

    Comparison vs cryolipolysis for equivalent submental reduction.

Key Study

ATX-101 (deoxycholic acid injection) for reduction of submental fat: results from a phase III, randomized, placebo-controlled study

Rzany et al. · Aesthetic Surgery Journal · 2014

Phase 3 RCT (n=506) demonstrated 68.2% of ATX-101 patients vs 20.5% placebo achieved clinician-rated improvement in submental fat at 12 weeks. Marginal mandibular nerve injury occurred in 4.3% of treated patients (all resolved within 6 weeks), and severe swelling and bruising in the majority of patients after each session.

PubMed ↗  PMID 24605812
Products on the market
BrandManufacturerWhat differentiates itApprovalPricing
KybellaAllergan (AbbVie)Only FDA-approved deoxycholic acid product; 2015 approval specifically for submental fat2015$1,200-2,000/session; 2-6 sessions typical
BelkyraAllerganSame deoxycholic acid formulation under EU and Canada brand nameCE/Health CanadaEquivalent to Kybella
CoolSculptingAllerganCryolipolysis alternative; non-injectable; different mechanism and risk profileFDA$600-1,500/area
LiposuctionSurgicalSurgical permanent fat removal; single procedure; surgical risk appliesN/A$2,000-5,000
Quick Facts
Duration20-30 min; 2-6 sessions needed; permanent fat reduction
Studies150+
FDA StatusFDA-approved (2015) for submental fat reduction
Price$1,200-$3,000 per session
Full list of studies reviewed
15 studies +
  1. 1.Dunican KC, et al. Deoxycholic Acid (ATX-101) for Reduction of Submental Fat. The Annals of pharmacotherapy. 2016.PMID 27340142 ↗
  2. 2.Ascher B, et al. ATX-101 (deoxycholic acid injection) for reduction of submental fat. Expert review of clinical pharmacology. 2016.PMID 27457304 ↗
  3. 3.Lin MJ, et al. The Impact of Submental Deoxycholic Acid Injections on Neck Surgery. Journal of drugs in dermatology : JDD. 2019.PMID 31860219 ↗
  4. 4.Ting W, et al. A Randomized, Double-Blind, Placebo-Controlled, Multicentered Study to Evaluate the Efficacy and Safety of MEI005 in Reducing Submental Fat in Chinese Adults. Aesthetic surgery journal. 2025.PMID 31860219 ↗
  5. 5.Dover JS, et al. Management of Patient Experience With ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2016.PMID 40037621 ↗
  6. 6.Ibáñez-Vicente C, et al. Current status of localized submental fat treatment with sodium deoxicolate (ATX-101). Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina. 2021.PMID 33655744 ↗
  7. 7.Rzany B, et al. Reduction of unwanted submental fat with ATX-101 (deoxycholic acid), an adipocytolytic injectable treatment: results from a phase III, randomized, placebo-controlled study. The British journal of dermatology. 2014.PMID 33655744 ↗
  8. 8.Ascher B, et al. Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study. Journal of the European Academy of Dermatology and Venereology : JEADV. 2014.PMID 24147933 ↗
  9. 9.Cohen JL, et al. Additional thoughts on the new treatment Kybella. Seminars in cutaneous medicine and surgery. 2015.PMID 24605812 ↗
  10. 10.Zhou W, et al. Chenodeoxycholic Acid-Loaded Nanoparticles Are Sufficient to Decrease Adipocyte Size by Inducing Mitochondrial Function. Nano letters. 2024.PMID 38278518 ↗
  11. 11.Shridharani SM, et al. Efficacy and Safety of Tapencarium (RZL-012) in Submental Fat Reduction. Aesthetic surgery journal. 2023.PMID 38278518 ↗
  12. 12.Rotunda AM, et al. Randomized double-blind clinical trial of subcutaneously injected deoxycholate versus a phosphatidylcholine-deoxycholate combination for the reduction of submental fat. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2009.PMID 19397673 ↗
  13. 13.Glogau RG, et al. A Double-Blind, Placebo-Controlled, Phase 3b Study of ATX-101 for Reduction of Mild or Extreme Submental Fat. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2019.PMID 30998531 ↗
  14. 14.Shridharani SM, et al. ATX-101 (Deoxycholic Acid Injection) Treatment in Men: Insights From Our Clinical Experience. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2017.PMID 30998531 ↗
  15. 15.Jones DH, et al. REFINE-1, a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial With ATX-101, an Injectable Drug for Submental Fat Reduction. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2016.PMID 28902021 ↗

Should You Try This?

15105OUT OF 10

Probably wait for more data

Questions to ask your doctor

  • Q1

    How many Kybella treatments have you performed and what is your marginal mandibular nerve injury rate?

    Good answer

    A good answer includes specific experience data and demonstrates understanding that marginal mandibular nerve injury is the primary risk, along with a management protocol if it occurs.

  • Q2

    How many sessions do you estimate I will need based on my anatomy?

    Good answer

    A good answer assesses submental volume and gives a realistic 2-6 session estimate grounded in your specific anatomy, not a minimal number designed to lower the apparent commitment.

  • Q3

    What should I plan for in the 2 weeks after each session?

    Good answer

    A good answer is clear about severe swelling, bruising, and numbness being expected and normal, and advises planning sessions away from important events.

Clinic checklist

Universal

  • Check the practitioner is licensed and registered. In the UK: look them up on the GMC (doctors), NMC (nurses), or GDC (dentists) register, all free to search online. In the US: search your state medical board. Takes 2 minutes. If they cannot tell you their regulatory body, leave.
  • Ask to see the product box before treatment. It should be factory-sealed with a visible lot number and expiry date. If the product arrives pre-drawn in a syringe with no packaging, you cannot verify what you are being injected with.
  • You should receive a written consent form before treatment. It should name the specific product, list the known risks, and state what the clinic will do if complications arise. A single generic form with no product name is not adequate.
  • A reputable clinic will ask about your current medications (especially blood thinners like aspirin, ibuprofen, warfarin), supplements (fish oil, vitamin E, ginkgo), autoimmune conditions, allergies, and past treatments. If no one asks, they are skipping a safety step.
  • Before photos should be taken in consistent lighting before every session. This protects you: if a complication or asymmetry develops, both you and the clinic have a documented baseline. If a clinic does not take before photos, they are not tracking outcomes.
  • Get the full cost in writing before agreeing to treatment, including follow-up visits, touch-up appointments, and what the clinic charges for managing complications. Verbal quotes are not binding.

Procedure-specific

  • Ensure only branded Kybella or Belkyra is used -- ask to see the sealed vial before treatment begins.
  • Schedule sessions so the 1-2 week recovery does not coincide with important personal or professional events.
  • Understand you need 2-6 sessions for full results; budget accordingly before committing to the first session.
  • Confirm the practitioner understands the anatomy of the marginal mandibular nerve and has a protocol if injury occurs.
  • Have realistic expectations about the recovery burden before committing to treatment.

Educational content only. This page summarises published clinical research and is not medical advice. Consult a qualified healthcare provider before making decisions about your care.

Researched by

Val Yermakova

Informed Girl · informedgirl.com